June 28, 2013
1 min read
Save

Anti-VEGF may hasten improvement in symptomatic retinal arterial macroaneurysms

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Intravitreal bevacizumab injection may speed improvement in macular edema and hemorrhage due to retinal arterial macroaneurysms, according to a study.

The retrospective study included 23 eyes of 23 patients with symptomatic retinal arterial macroaneurysm; 11 eyes were treated with Avastin (bevacizumab, Genentech) and a control group comprised 12 untreated eyes.

Bevacizumab was injected at the first visit and subsequently on a monthly as-needed basis; treated eyes received a mean 1.42 injections.

LogMAR best corrected visual acuity and central macular thickness were evaluated at 1, 3 and 6 months after initiation of treatment and at the final visit; mean follow-up was 10.83 months.

BCVA and central macular thickness improved significantly and remained stable in both groups at final follow-up.

In the bevacizumab group, BCVA was significantly improved after 1 month, while in the control group, BCVA was significantly improved after 3 months.

By the end of follow-up, the between-group differences in BCVA and central macular thickness improvement were insignificant.